ArticleAntimicrobial agents and chemotherapy2021
Evaluation of Susceptibility Testing Methods for Aztreonam and Ceftazidime-Avibactam Combination Therapy on Extensively Drug-Resistant Gram-Negative Organisms.
Open access · hybridAbstract read
In one paragraph
Article in Antimicrobial agents and chemotherapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed, 2 pooled it
4.0field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 2 syntheses or guidelines pooled it, 76 citations in OpenAlex.
- Global trends of ceftazidime-avibactam resistance in gram-negative bacteria: systematic review and meta-analysis.Antimicrobial resistance and infection control · 2025Pooled it
- In search for a synergistic combination against pandrug-resistant A. baumannii; methodological considerations.Infection · 2022Pooled it
- Assessing the Synergistic Potential of Ceftazidime-avibactam and Aztreonam against Metallo-beta-lactamase Producing Enterobacterales by Disc Elution and Disc E Strip - Synergy Method.Annals of African medicine · 2026Article
- The Evolving Clonal, Plasmid-Mediated Resistome, Virulome and Therapeutic Landscape of Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- Saturated fatty acids enhance daptomycin activity in a Fak-dependent manner in enterococci.Microbiology (Reading, England) · 2026Article
- Comparison of laboratory-developed methods for aztreonam plus ceftazidime-avibactam antimicrobial susceptibility testing for metallo-beta-lactamase-producing Enterobacterales.Journal of clinical microbiology · 2026Article
- Susceptibility to novel antimicrobial agents and molecular epidemiology of carbapenem-resistant enterobacterales: a 9-year study in Central China.BMC microbiology · 2026Article
- Clinical and genomic determinants associated with emergent ceftazidime-avibactam plus aztreonam non-susceptibility in ceftazidime-avibactam resistantAntimicrobial agents and chemotherapy · 2026Article
- Comparison of agar-based methodologies to broth disc elution for the detection of aztreonam susceptibility in the presence of ceftazidime-avibactam.Microbiology spectrum · 2026Article
- Rapid Detection of Carbapenemase-Producing Enterobacterales Using a Luminescent Whole-Cell Biosensor.ACS infectious diseases · 2026Article
- DOT-MGA for rapid determination of susceptibility to the combination of Ceftazidime-avibactam and Aztreonam among Enterobacterales.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2025Article
- Antimicrobial Susceptibility Testing of the Combination of Aztreonam and Avibactam in NDM-ProducingAntibiotics (Basel, Switzerland) · 2025Article
- Management of Carbapenem Resistant Gram-Negative Infections.Indian journal of pediatrics · 2025Review
- Improved diagnostic stewardship in carbapenem-resistantJournal of medical microbiology · 2025Article
- Prevalence of New Delhi Metallo-β-lactamase (blaMolecular biology reports · 2025Article
- Evaluation of two gradient diffusion tests to determine susceptibility to aztreonam and ceftazidime-avibactam in combination.Antimicrobial agents and chemotherapy · 2025Article
- Synergistic combination of ceftazidime and avibactam with Aztreonam against MDR Klebsiella pneumoniae in ICU patients.Scientific reports · 2025Article
- Resistance profiles of carbapenemase-producing Enterobacterales in a large centre in England: are we already losing cefiderocol?The Journal of antimicrobial chemotherapy · 2025Article
- Aztreonam Acts as a Synergist for Ceftazidime/Avibactam Against Carbapenem-ResistantInfection and drug resistance · 2025Article
- Analysis of a simple disk diffusion method to evaluate ceftazidime-avibactam/aztreonam combination synergism against New Delhi metallo-beta-lactamase-producing clinical isolates.Access microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Ayesha KhanCenter for Antimicrobial Resistance and Microbial Genomics, Division of Infectious Diseases, UTHealth, McGovern Medical School, UTHealth, Houston, Texas, USA.ORCID 0000-0002-0489-0712
Samuel G EricksonCenter for Antimicrobial Resistance and Microbial Genomics, Division of Infectious Diseases, UTHealth, McGovern Medical School, UTHealth, Houston, Texas, USA.
Cedric PettawayCenter for Antimicrobial Resistance and Microbial Genomics, Division of Infectious Diseases, UTHealth, McGovern Medical School, UTHealth, Houston, Texas, USA.
Cesar A AriasCenter for Antimicrobial Resistance and Microbial Genomics, Division of Infectious Diseases, UTHealth, McGovern Medical School, UTHealth, Houston, Texas, USA.
William R MillerCenter for Antimicrobial Resistance and Microbial Genomics, Division of Infectious Diseases, UTHealth, McGovern Medical School, UTHealth, Houston, Texas, USA.ORCID 0000-0002-1518-2973
Micah M BhattiDepartment of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Centergrid.240145.6, Houston, Texas, USA.ORCID 0000-0001-5857-5825
The University of Texas Health Science Center at Houston · USThe University of Texas MD Anderson Cancer Center · USUniversity of Texas Health Science Center at Dallas · US
Funding
Project 3: Functional Microbiome and Host Signatures in Transition from Commensal to pathogenP01AI152999 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI HAAG, ANTHONY · 2020 to 2025
$12.0MVENOUS: A translational study of enterococcal bacteremiaR01AI148342 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI ARIAS, CESAR AUGUSTO · 2020 to 2024
$3.9MThe LiaFSR system and antimicrobial peptide resistance in enterococciR01AI134637 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI Cesar Augusto Arias · 2018 to 2026
$3.7MMolecular Mechanisms Of Daptomycin Resistance In EnterococciR01AI093749 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI ARIAS, CESAR AUGUSTO · 2011 to 2015
$1.9MPOR Program on Genomic Prediction of Antimicrobial Resistance in VREK24AI121296 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI ARIAS, CESAR AUGUSTO · 2016 to 2025
$1.5MRole of YxdJK and DAK in the Enterococcal Envelope Stress ResponseK08AI135093 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI MILLER, WILLIAM R · 2018 to 2022
$929kNIAID NIH HHS K08 AI135093NIAID NIH HHS K24 AI121296NIAID NIH HHS P01 AI152999NIAID NIH HHS R01 AI093749NIAID NIH HHS R01 AI134637NIAID NIH HHS R01 AI148342
Abstract
Carbapenem-resistant
Indexed as
Anti-Bacterial AgentsAztreonamAzabicyclo Compoundsbeta-LactamasesCeftazidimeDrug CombinationsMicrobial Sensitivity TestsPseudomonas aeruginosaAnti-Bacterial Agentsavibactam, ceftazidime drug combinationAzabicyclo CompoundsAztreonambeta-LactamasesCeftazidimeDrug Combinationsantibiotic resistanceantimicrobial combinationsbeta-lactamasescarbapenemsclinical methodsdiagnosticsEnterobacteriaceaemetalloenzymesmultidrug resistancesusceptibility testing
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.